European Medicines Agency’s data protection notice for women leadership development and mentoring activities

Minutes - HMA-EMA joint Network Data Steering Group meeting - 11 February 2026

Concept paper on the development of a reflection paper on proof-of-concept data to support the development of anti-cancer medicinal products in paediatric patients

Development of anti-cancer medicinal products in paediatric patients - Scientific guideline

Human medicines European public assessment report (EPAR): Elucirem, gadopiclenol, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Vueway, gadopiclenol, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), lenalidomide, Date of authorisation: 11/02/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Quviviq, daridorexant, Date of authorisation: 29/04/2022, Revision: 11, Status: Authorised

Herbal medicinal product: Zingiberis rhizoma, Zingiber officinale Roscoe, F: Assessment finalised

Herbal medicinal product: Trigonellae foenugraeci semen, Trigonella foenum-graecum  L., F: Assessment finalised